BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Kawakami K, Inoue T, Murano M, Narabayashi K, Nouda S, Ishida K, Abe Y, Nogami K, Hida N, Yamagami H, Watanabe K, Umegaki E, Nakamura S, Arakawa T, Higuchi K. Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitis. World J Gastroenterol 2015; 21(6): 1880-1886 [PMID: 25684955 DOI: 10.3748/wjg.v21.i6.1880]
URL: https://www.wjgnet.com/1007-9327/full/v21/i6/1880.htm
Number Citing Articles
1
Iago Rodríguez-Lago, Jesús Castro-Poceiro, Agnès Fernández-Clotet, Francisco Mesonero, Antonio López-Sanromán, Alicia López-García, Lucía Márquez, Ariadna Clos-Parals, Fiorella Cañete, Miren Vicuña, Óscar Nantes, Olga Merino, Virginia Matallana, Jordi Gordillo, Ainara Elorza, Raquel Vicente, María José Casanova, Rocío Ferreiro-Iglesias, Pablo Pérez-Galindo, José Manuel Benítez, Carlos Taxonera, María José García, Eduardo Martín, Urko Aguirre, Javier P. Gisbert. Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics 2020; 51(9): 870 doi: 10.1111/apt.15687
2
Keiichi Haga, Tomoyoshi Shibuya, Kei Nomura, Koki Okahara, Osamu Nomura, Dai Ishikawa, Naoto Sakamoto, Taro Osada, Akihito Nagahara. Effectiveness and Nephrotoxicity of Long-Term Tacrolimus Administration in Patients with Ulcerative ColitisJournal of Clinical Medicine 2020; 9(6): 1771 doi: 10.3390/jcm9061771
3
Biyu Wu, Jinglu Tong, Zhihua Ran. Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A ReviewInflammatory Bowel Diseases 2020; 26(1): 24 doi: 10.1093/ibd/izz068
4
Peter Hoffmann, Cyrill Wehling, Johannes Krisam, Jan Pfeiffenberger, Nina Belling, Annika Gauss. Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitisWorld Journal of Gastroenterology 2019; 25(13): 1603-1617 doi: 10.3748/wjg.v25.i13.1603
5
Katsuyoshi Matsuoka, Eiko Saito, Toshimitsu Fujii, Kento Takenaka, Maiko Kimura, Masakazu Nagahori, Kazuo Ohtsuka, Mamoru Watanabe. Tacrolimus for the Treatment of Ulcerative ColitisIntestinal Research 2015; 13(3): 219 doi: 10.5217/ir.2015.13.3.219
6
Mukta Gupta, Vijay Mishra, Monica Gulati, Bhupinder Kapoor, Amrinder Kaur, Reena Gupta, Murtaza M. Tambuwala. Natural compounds as safe therapeutic options for ulcerative colitisInflammopharmacology 2022; 30(2): 397 doi: 10.1007/s10787-022-00931-1
7
Yuichi Muraki, Shugo Mizuno, Kaname Nakatani, Hiroki Wakabayashi, Eiji� Ishikawa, Toshimitsu Araki, Akira Taniguchi, Shuji Isaji, Masahiro Okuda. Monitoring of peripheral blood cluster of differentiation 4+ adenosine triphosphate activity and CYP3A5 genotype to determine the pharmacokinetics, clinical effects and complications of tacrolimus in patients with autoimmune diseasesExperimental and Therapeutic Medicine 2017;  doi: 10.3892/etm.2017.5364
8
Sukrit Sud, Sanjeev Sachdeva, Amarender Singh Puri. Tacrolimus as rescue therapy for steroid-dependent/steroid-refractory ulcerative colitis: Experience from tertiary referral center in IndiaIndian Journal of Gastroenterology 2021; 40(6): 598 doi: 10.1007/s12664-021-01185-5
9
Juan LASA, Pablo OLIVERA. EFFICACY OF TACROLIMUS FOR INDUCTION OF REMISSION IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSISArquivos de Gastroenterologia 2017; 54(2): 167 doi: 10.1590/s0004-2803.201700000-15
10
Jing-Jing Wang, Yi-Hong Fan. Advances in research of tacrolimus for treatment of inflammatory bowel diseaseWorld Chinese Journal of Digestology 2019; 27(13): 842 doi: 10.11569/wcjd.v27.i13.842
Abstract() |  Core Tip() |  Full Article(HTML)() | Times Cited  (0) | Total Visits (0) | Open
11
Dai Ishikawa, Takashi Sasaki, Taro Osada, Kyoko Kuwahara-Arai, Keiichi Haga, Tomoyoshi Shibuya, Keiichi Hiramatsu, Sumio Watanabe. Changes in Intestinal Microbiota Following Combination Therapy with Fecal Microbial Transplantation and Antibiotics for Ulcerative ColitisInflammatory Bowel Diseases 2017; 23(1): 116 doi: 10.1097/MIB.0000000000000975
12
Iago Rodríguez-Lago, Olga Merino, Óscar Nantes, Carmen Muñoz, Urko Aguirre, José Luis Cabriada. Previous exposure to biologics and C-reactive protein are associated with the response to tacrolimus in inflammatory bowel diseaseRevista Española de Enfermedades Digestivas 2016; 108 doi: 10.17235/reed.2016.4447/2016
13
Takayasu Suzuka, Takuya Kotani, Tohru Takeuchi, Youhei Fujiki, Kenichiro Hata, Shuzo Yoshida, Takeshi Shoda, Shigeki Makino, Shigeki Arawaka. Efficacy and safety of oral high-trough level tacrolimus in acute/subacute interstitial pneumonia with dermatomyositisInternational Journal of Rheumatic Diseases 2019; 22(2): 303 doi: 10.1111/1756-185X.13414
14
K. J. Schmidt, N. Müller, A. Dignass, D. C. Baumgart, H. Lehnert, E. F. Stange, K. R. Herrlinger, K. Fellermann, J. Büning. Long-term Outcomes in Steroid-refractory Ulcerative Colitis Treated with Tacrolimus Alone or in Combination with Purine AnaloguesJournal of Crohn's and Colitis 2016; 10(1): 31 doi: 10.1093/ecco-jcc/jjv175
15
Natsuki Ishida, Takahiro Miyazu, Satoshi Tamura, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto. Early serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcomeWorld Journal of Gastroenterology 2021; 27(22): 3109-3120 doi: 10.3748/wjg.v27.i22.3109
16
Yuto Yamada, Yuta Ohno, Takashi Niwa, Hiroko Kato‐Hayashi, Hideki Hayashi, Takashi Ibuka, Hiroshi Araki, Tadashi Sugiyama, Masahito Shimizu, Akio Suzuki. Rapid attainment of target trough concentrations of tacrolimus for early improvement of clinical symptoms in patients with ulcerative colitisJournal of Clinical Pharmacy and Therapeutics 2019; 44(3): 409 doi: 10.1111/jcpt.12800
17
Yujiro Henmi, Kazuki Kakimoto, Takuya Inoue, Kei Nakazawa, Minori Kubota, Azusa Hara, Takashi Mikami, Yutaka Naka, Yuki Hirata, Yoshimasa Hirata, Taisuke Sakanaka, Sadaharu Nouda, Toshihiko Okada, Ken Kawakami, Toshihisa Takeuchi, Kazunari Tominaga, Kazuhide Higuchi. Cytomegalovirus infection in ulcerative colitis assessed by quantitative polymerase chain reaction: risk factors and effects of immunosuppressantsJournal of Clinical Biochemistry and Nutrition 2018; 63(3): 246 doi: 10.3164/jcbn.18-14
18
Yuga Komaki, Fukiko Komaki, Akio Ido, Atsushi Sakuraba. Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysisJournal of Crohn's and Colitis 2016; 10(4): 484 doi: 10.1093/ecco-jcc/jjv221
19
Calvin J. Meaney, Spinel Karas. A Worldwide Yearly Survey of New Data in Adverse Drug ReactionsSide Effects of Drugs Annual 2016; 38: 407 doi: 10.1016/bs.seda.2016.08.001
20
Hilal Ahmad, Vijay L. Kumar. Pharmacotherapy of ulcerative colitis – current status and emerging trendsJournal of Basic and Clinical Physiology and Pharmacology 2018; 29(6): 581 doi: 10.1515/jbcpp-2016-0014
21
Peter Townsend, Jeffrey S. Hyams. Pediatric Inflammatory Bowel Disease2017; : 95 doi: 10.1007/978-3-319-49215-5_8
22
George Salem, Kai Ding, Atsushi Sakuraba, Russell Cohen. Role of topical tacrolimus in the management of proctitis, perianal manifestations in Crohn’s disease, and chronic pouchitis: a systematic reviewJournal of Investigative Medicine 2021; 69(4): 796 doi: 10.1136/jim-2020-001699